Charles Duncan

Charles Duncan

Director/Board Member at VANDA PHARMACEUTICALS INC.

Net worth: 291 215 $ as of 2026-07-30

63 year
Finance
Consumer Services
Health Technology

Profile

Charles C.
Duncan
is an Independent Director at Vanda Pharmaceuticals, Inc. starting in 2026.
Former positions include Biotechnology Analyst at Cantor Fitzgerald & Co. from 2018 to 2025, Senior Research Analyst at Piper Sandler & Co. from 2014 to 2018, Managing Director & Senior Analyst at Citizens JMP Securities LLC in 2012, Analyst roles at Prudential Securities, Chatfield Dean & Co., Inc., and Tucker Anthony Cleary Gull, and Principal at Dresdner Kleinwort Wasserstein Group, Inc. Education includes undergraduate studies at the University of Wisconsin and a doctorate from The University of Colorado.

Known holdings in public companies

CompanyDateNumber of sharesValuationValuation date
2026-06-03 57,101 ( 0.09% ) 291 215 $ 2026-07-30

Charles Duncan active positions

CompaniesPositionStart
VANDA PHARMACEUTICALS INC. Director/Board Member 2026-04-21

Former positions of Charles Duncan

CompaniesPositionEnd
Analyst-Equity 2025-05-31
Analyst-Equity 2018-06-30
Analyst-Equity 2012-11-29
Corporate Officer/Principal -
Corporate Officer/Principal -
See the detail of Charles Duncan's experience

Training of Charles Duncan

Experiences
Positions held

Active

Inactive

Listed companies

Private companies

Connections

97

1st degree connections

10

1st degree companies

Male

Female

Members of the board

Executives

Linked companies

Private companies10

Finance

Finance

Finance

Finance

Health Technology

Finance

Finance

Consumer Services

Consumer Services

Dresdner Kleinwort Wasserstein Group, Inc.

  1. Stock Market
  2. Insiders
  3. Charles Duncan